陶在痴呆症与莱维体的痴呆症
Kai Sin Chin1,2,3, Leonid Churilov4, Vincent Doré5,6
1Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.
The Australian and New Zealand journal of psychiatry
|June 2, 2023
概括
血p-tau181显示为生物标志物,用于检测同时发生的阿尔茨海默氏症病理在痴呆症与勒维体. 这种血液测试与异常的和粉样蛋白PET扫描相关,有助于识别混合病理.
科学领域:
- 神经学 神经学
- 神经成像是一种神经成像.
- 生物标志物发现发现
背景情况:
- 神经纤维状结,阿尔茨海默病的标志,在一些痴呆症与勒维体 (DLB) 病例中发现,可能会恶化认知能力下降.
- 阿尔茨海默病生物标志物的进展包括第二代定子发射断层扫描 (PET) 和化在threonine 181 (p-tau181) 的血检测.
研究的目的:
- 研究患有勒维体痴呆症的人群中病理的存在和影响.
- 评估第二代tau PET成像和血p-tau181作为DLB中的生物标志物的实用性.
主要方法:
- 27名可能患有DLB的参与者使用F-MK6240和F-NAV4694标记器进行了PET成像.
- 使用Simoa技术量化了血p-tau181水平.
主要成果:
- 18.5%的DLB参与者表现出异常的TAU PET扫描.
- 血p-tau181度与时间沉积 (ρ = 0.46) 呈正相关性,并预测异常的PET.
- 血p-tau181还与粉样β-PET结合相关 (ρ = 0.68),并预测了异常的粉样β-PET.
结论:
- 陶病理是一种常见的同时发生的疾病,在痴呆症中与莱维体一起发生.
- 血p-tau181可以作为一种有价值的基于血液的标记物,用于识别DLB的伴随性阿尔茨海默病相关病理.
- 需要进一步的大规模纵向研究来阐明TAU在DLB的临床意义.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.9K
09:33Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
Published on: July 28, 2013
28.5K
相关概念视频
01:30Dementia
144
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
144
01:26Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539
01:37Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
01:24Parkinson's Disease: Treatment
308
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
308
01:15Parkinson's Disease: Overview
614
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
614
01:22Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226